Kevin A. Lobo

Chair, Chief Executive Officer, and President at STRYKER

Board

Since 2021

Age

59 years

Tenure

Joined SYK in 2011 as an executive officer and Group President of Stryker Orthopaedics, then promoted to Chief Executive Officer and President in 2012, became Chair in 2014, served as both Chair and CEO from 2018 to 2021, and resumed the role of President in 2021.

Also at STRYKER

GSB

Glenn S. Boehnlein

Vice President, Chief Financial Officer (until April 1, 2025)

JAP

J. Andrew Pierce

Group President, MedSurg and Neurotechnology

MKF

M. Kathryn Fink

Vice President, Chief Human Resources Officer

About

Kevin A. Lobo is a seasoned leader in the medical technology industry with 59 years of life experience, hailing from the United States. He has built a solid reputation for steering Stryker Corporation through multiple leadership roles while demonstrating a commitment to innovation and growth.

He began his journey at SYK in 2011 as an executive officer and Group President of Stryker Orthopaedics, rapidly ascending the corporate ladder. In 2012, he took on the dual roles of Chief Executive Officer and President, followed by his appointment as Chair in 2014, reflecting a series of impactful promotions that solidified his influence within the company.

Beyond his core roles at SYK, he has extended his expertise to other prominent organizations, holding directorships at The Advanced Medical Technology Association and Parker-Hannifin Corporation, and serving as Chair of the Valley Health System Board of Trustees. His multifaceted career highlights a blend of strong corporate governance and strategic vision in both his professional and community engagements.

$SYK Performance Under Kevin A. Lobo

Past Roles

Organization	Role	Date Range	Details
Stryker Corporation	Group President, Stryker Orthopaedics	2011-2012	Held position prior to promotion to CEO and President
Johnson & Johnson	Various Leadership Roles	2003-2011	Held multiple leadership roles before joining Stryker

External Roles

Organization	Role	Date Range
The Advanced Medical Technology Association (AdvaMed)	Director	N/A
Parker-Hannifin Corporation	Director	N/A

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$1,400,000	Annual	3.7% increase vs 2022
Actual Salary Paid	$1,391,667	As Paid	Reported in the Salary column
Deferred Contributions	N/A	Deferred	Portion deferred into 401(k) and Supplemental Plan

Performance Compensation

Data from FY 2023

Bonus Plan - Core Performance Metrics

Metric	Weight	Threshold	Target	Actual Performance	Details
Adjusted Operating Income	20%	$4.266B	$4.788B	$4.972B	Basis for 20% payout calculation
Adjusted Operating Income Margin	20%	23.66%	23.96%	24.28%	Margin improvement
Constant Currency Sales	40%	$18.793B	$19.783B	$20.480B	Sales growth metric
Free Cash Flow Excluding Recall Payments	20%	$2.326B	$2.764B	$3.172B	Cash flow performance

Bonus Plan - Overachievement Bonus Metrics

Metric	Weight	Target	Actual Performance	Details
Adjusted Operating Income	20%	$4.932B	$4.972B	Additional bonus component
Constant Currency Sales	30%	$20.178B	$20.480B	Additional bonus component
Free Cash Flow Excluding Recall Payments	20%	$2.931B	$3.172B	Additional bonus component
Adjusted Net Earnings Per Diluted Share	30%	$10.29	$10.60	Earnings performance metric

Modifier: Potential bonus payout adjustment of +/-10% based on progress toward CR commitments.

Non-Equity Incentive Plan Compensation

Metric	Amount	Details
Target Bonus	$2,100,000	Set as the target bonus
Maximum Bonus	$4,200,000	Maximum payout opportunity (up to an additional 100% of target)
Actual Bonus Payment	$3,780,000	Represents 180% of the target bonus
Operating Income Minimum	$3.79B	Minimum adjusted consolidated operating income required before bonus accrual
Modifier	+/-10%	Adjustment based on CR commitments (carbon emissions & diversity, equity & inclusion)

Performance Stock Units (PSUs)

Metric	Value	Details
Grant Date	Feb 9, 2023	Performance period: 2023–2025
Threshold	12,582 units	Minimum performance level
Target	25,166 units	Performance target
Maximum	50,332 units	200% of target
Grant Date Fair Value	$6,652,884	Based on the target outcome
Vesting Date	Mar 21, 2026	Vesting contingent on achieving performance goals
Conditions	N/A	Minimum adjusted net earnings per diluted share required

Option Awards

Metric	Value	Details
Grant Date	Feb 9, 2023	Options are time-based and not tied to performance metrics
Number of Options Granted	100,665
Exercise Price	$268.22/share
Grant Date Stock Price	$264.36/share
Grant Date Fair Value	$8,410,645	Valued using the Black-Scholes model
Vesting Schedule	20% per year for 5 years	20% vesting on each anniversary of the grant date
Option Expiration	Feb 8, 2033	10-year term